Corona Remedies Ltd

Corona Remedies Ltd reported a strong start to FY27 with unaudited financial results for Q1FY27. Revenue from operations grew by 21.9% year-on-year to ₹422.4 Cr, driven by robust brand building and operational excellence. Profit After Tax (PAT) increased by 30.1% year-on-year to ₹60.1 Cr, with PAT margins improving by 90 basis points to 14.2%. The company continues to outperform the Indian Pharmaceutical Market (IPM) and has moved up to the 26th rank. Key business highlights include the inauguration of an EU-GMP approved Female Hormone Manufacturing Facility and the integration of the acquired brand Wokadine. The company remains focused on core therapies like Women's Healthcare and Cardio-diabetes.

Corona Remedies Ltd announced the outcome of its Board Meeting held today, wherein the Board approved the unaudited standalone and consolidated financial results for the first quarter and three months ended June 30, 2026. The company also approved the limited review reports for the same period. These results will be published in an advertisement as per listing regulations and will be available on the company's website. The Board meeting commenced at 3:00 p.m. and concluded at 4:00 p.m.

Corona Remedies opened FY27 with a clean growth print: consolidated revenue rose 21.9% YoY to ₹422.4 Cr and net profit climbed 30.1% YoY to ₹60.1 Cr (₹46.2 Cr a year ago), with net margin widening ~90 bps to 14.2%. Profit outgrew revenue with no help from one-offs — neither the current nor year-ago quarter carries an exceptional item, so the reported +30.1% is also the underlying figure. Standalone tells the same story (PAT ₹60.1 Cr); the consolidated line differs by just ₹0.01 Cr of associate profit, so the two bases are effectively identical here. The margin expansion is operating-led. Management's disclosed EBITDA rose 33.5% to ₹93.1 Cr with EBITDA margin up 190 bps YoY to 22.0%, driven by brand-building and operational leverage: revenue grew faster than employee costs (₹122.1 Cr, +25%) and other expenses (₹129.7 Cr, +14%), while cost of materials stayed contained. Sequentially the print looks even stronger — revenue +19.6% and PAT +32.6% over Q4 FY26's ₹353.1 Cr / ₹45.3 Cr — but Q4 was a soft base, so YoY is the cleaner read. The board declared the results 31 July; the earnings call is set for 3 August. Against the bar, this is a beat-to-meet. Management's FY27 guidance from the Q4 concall was >15% organic revenue growth and >20% PAT growth; Q1 delivered 21.9% and 30.1%, comfortably ahead on both. Street context was thin for this December-2025 IPO — Univest's preview pegged Q1 PAT in a ₹58–74 Cr range, and the actual ₹60.1 Cr lands in the lower-middle of it, so inline rather than a blowout. Operationally, management flags Corona as the fastest-growing among IPM's top-30 for six straight months, rank up three places to 26th (MAT June'26), and 5th in Gynaecology. The quarter also saw commercialisation of the EU-GMP female hormone facility (30 June) and the start of Wokadine integration — both feeding the chronic/women's-health focus that underpins the guidance.

Corona Remedies Ltd has announced that its Board of Directors will convene on July 31, 2026. The primary agenda for this meeting is to consider and approve the company's Unaudited Financial Results for the first quarter and three months ended June 30, 2026. Both standalone and consolidated results will be reviewed. The trading window for the company's securities will remain closed until August 02, 2026, following an earlier intimation regarding insider trading regulations.

Corona Remedies Ltd has announced the commencement of commercial production at its new EU-GMP approved Women's Hormone manufacturing facility located in Bhayla, Ahmedabad. This state-of-the-art facility, inaugurated by Chairman Dr. K. L. Mehta and long-serving women employees, is designed to meet the growing global demand for specialized hormone therapies. The facility boasts advanced manufacturing technologies, including closed-loop systems and precision environmental controls, with an annual capacity of 194 million tablets/capsules and 1.5 million ointments/gels. This expansion is expected to increase the company's in-house hormone manufacturing capacity by nearly 20%, reinforcing its commitment to women's healthcare and strengthening India's pharmaceutical manufacturing capabilities for both domestic and international markets.

Corona Remedies Ltd has announced the inauguration and commencement of commercial production at its EU-GMP approved Women's Hormone manufacturing facility in Bhayla, Ahmedabad. This state-of-the-art facility is designed for specialized hormone manufacturing, featuring segregated operations, precision environmental controls, and advanced containment technologies. It supports multiple dosage forms including tablets, soft gel capsules, ointments, and gels, with an annual capacity of 194 million tablets/capsules and 1.5 million ointments/gels. The facility's commissioning is expected to increase Corona Remedies' in-house hormone manufacturing capacity by nearly 20%, reinforcing its commitment to women's healthcare and strengthening its capabilities for domestic and international markets.

Corona Remedies Ltd has announced the closure of its trading window for dealing in the company's securities. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be shut from July 01, 2026, until 48 hours after the declaration of the unaudited financial results for the first quarter ending June 30, 2026. The date for the board meeting to consider these results will be communicated separately.

Sepia Investments Ltd, Anchor Partners, and Sage Investment Trust have collectively sold a significant number of equity shares in Corona Remedies Limited. Specifically, Sepia Investments sold 4,328,943 shares, Anchor Partners sold 161,861 shares, and Sage Investment Trust sold 90,087 shares. This disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The transactions involve the sale of equity shares of a company listed on both BSE and NSE.

Sepia Investments Limited, Anchor Partners, and Sage Investment Trust have collectively sold 4,581,791 equity shares, representing approximately 7.5% of the total share capital, in Corona Remedies Limited. The sale was disclosed under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. Prior to the sale, these entities held a combined 20.91% stake in the company, which is listed on both BSE and NSE. The disclosure details the number of shares sold and the percentage of total share capital they represent.

Invesco Mutual Fund, through various schemes including Invesco India Consumption Fund and Invesco India Smalleap Fund, has disclosed its aggregate holding in Corona Remedies Limited. As of June 17, 2026, their total shareholding stands at 5.0562% of the company's paid-up share capital. This disclosure is made in compliance with Regulation 29(1) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The acquisition involved an increase of 0.4726%, bringing their total shares to 30,92,372.